Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 31, Issue 1, 2014, Pages 46-54

  Sweiss, Nadera J ^a   Noth, Imre ^b   Mirsaeidi, Mehdi ^c   Zhang, Wei ^c   Naureckas, Edward T ^b   Hogarth, D Kyle ^b   Strek, Mary ^b   Caligiuri, Philip ^d   Machado, RobertoF ^c   Niewold, TimothyB ^e   Garcia, Joe G N ^c   Pangan, Aileen L ^f   Baughman, Robert P ^g  

^a UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e MAYO GRADUATE SCHOOL   (United States)

^f ABBVIE INC   (United States)

^g UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Adalimumab; Anti TNF antibody; Pulmonary sarcoidosis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISONE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

6 MINUTE WALK DISTANCE; 6 MINUTE WALK TEST; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG SARCOIDOSIS; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPIRATORY TRACT PARAMETERS; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; MIDDLE AGED; PROSPECTIVE STUDY; SARCOIDOSIS, PULMONARY; TIME FACTOR;

ADALIMUMAB; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SARCOIDOSIS, PULMONARY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84900564369     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, Terrin ML, Weinberger SE, Moller DR, McLennan G, Hunninghake G, DePalo L, Baughman RP, Iannuzzi MC, Judson MA, Knatterud GL, Thompson BW, Teirstein AS, Yeager H, Jr., Johns CJ, Rabin DL, Rybicki BA, Cherniack R. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004; 170: 1324-1330. (Pubitemid 39657197)
2. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736-755.
3. Rybicki BA, Major M, Popovich J, Jr., Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997; 145: 234-241.
4. Baughman RP, Lower EE. New therapies for sarcoidosis. Clin Pulm Med 2004; 11: 154-160. (Pubitemid 38691659)
5. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155: 846-851.
6. Martin WJ, 2nd, Iannuzzi MC, Gail DB, Peavy HH. Future directions in sarcoidosis research: summary of an NHLBI working group. Am J Respir Crit Care Med 2004; 170: 567-571. (Pubitemid 39209141)
7. Bachwich PR, Lynch JP, 3rd, Larrick J, Spengler M, Kunkel SL. Tumor necrosis factor production by human sarcoid alveolar macrophages. Am J Pathol 1986; 125: 421-425. (Pubitemid 17208825)
8. Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990; 115: 36-42. (Pubitemid 20044133)
9. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336: 1224-1234. (Pubitemid 27183653)
10. Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum 2005; 53: 788-791. (Pubitemid 41463847)
11. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 2006; 25: 596-597. (Pubitemid 44137652)
12. Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller W, Jr., Sands BE, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, Muller-Quernheim J, Schlenker-Herceg R, Flavin S, Lo KH, Oemar B, Barnathan ES. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 201-208. (Pubitemid 47596315)
13. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, Muller-Quernheim J, Schlenker-Herceg R, Flavin S, Lo KH, Oemar B, Barnathan ES. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802. (Pubitemid 44511661)
14. Lahmer T, Knopf A, Lanzl I, Heemann U, Thuermel K, Kaiser CA, Cozzio A, Hofbauer GF, Kamarashev J, French LE, Navarini AA. Using TNF-alpha antagonist Adalimumab for treatment for multi-system sarcoidosis: a case study. Disfiguring annular sarcoidosis improved by adalimumab. Rheumatol Int 2011; 5: 5.
15. Kaiser CA, Cozzio A, Hofbauer GF, Kamarashev J, French LE, Navarini AA. Disfiguring annular sarcoidosis improved by adalimumab. Case Rep Dermatol 2011; 3: 103-106.
16. Hasni SA, Kunz D, Finzel K, Gruber BL. Osseous sarcoidosis treated with tumor necrosis factor-inhibitors: case report and review of the literature. Spine (Phila Pa 1976) 2010; 35: E904-907.
17. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-279.
18. Milman N, Graudal N, Loft A, Mortensen J, Larsen J, Baslund B. Effect of the TNF-alpha inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDGPET. Clin Respir J 2011.
19. Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2011; 27: 27.
20. Burns AM, Green PJ, Pasternak S. Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab. J Cutan Pathol 2012; 39: 289-293.
21. Field S, Regan AO, Sheahan K, Collins P. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol 2010; 35: 795-796.
22. Sweiss NJ, Noth I, Baughman RP, Ellman M, Curran J, Hogarth DK, Strek M, Alegre M, Clark M, Hires A, Caligiuri P, Pangan A. Adalimumab as a Novel Therapy for Refractory Sarcoidosis: Preliminary Results of a 52-Week Trial. American College of Rheumatology Annual Meeting; Boston, MA 2007.
23. Sweiss NJ, Noth IN, Baughman RP, Curran J, Naureckas E, Hogarth DK, Strek M, Caligiuri P, Alegre M, Niewold T, Pangan A, Ellman M. 52-Week Trial Results of Adalimumab as Novel Therapy for Refractory, Progressive Pulmonary Sarcoidosis. American Thoracic Society 2010 International Conference; New Orleans, LA 2010; Abstract A2370.
24. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 1970; 2: 92-98.
25. Borg G. Human Kinetics. Champaign, IL; 1998.
26. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999; 42: 2220-2230. (Pubitemid 30263609)
27. Muers MF, Middleton WG, Gibson GJ, Prescott RJ, Mitchell DN, Connolly CK, Harrison BD. A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society Study of Long-Term Corticosteroid Treatment. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14: 46-56. (Pubitemid 27170555)
28. Baughman RP CD, Grutters JC, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29: 90-98.
29. Steffen M, Petersen J, Oldigs M, Karmeier A, Magnussen H, Thiele HG, Raedler A. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J Allergy Clin Immunol 1993; 91: 939-949. (Pubitemid 23118511)
30. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005; 127: 1064-1071. (Pubitemid 40775543)
31. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 20: 119-130.
32. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama 2006; 295: 2275-2285. (Pubitemid 43736578)
33. Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010; 62: 755-763.
34. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
35. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361: 1111-1118. (Pubitemid 36369566)
36. Baughman RP, Lower EE. Fungal infections as a complication of therapy for sarcoidosis. Qjm 2005; 98: 451-456. (Pubitemid 40796817)
37. Baughman RP, Meyer KC, Nathanson I, Angel L, Bhorade SM, Chan KM, Culver D, Harrod CG, Hayney MS, Highland KB, Limper AH, Patrick H, Strange C, Whelan T. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 142: e1S-e111S.
38. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-1239. (Pubitemid 47300424)
39. Kamphuis LS, Lam-Tse WK, Dik WA, van Daele PL, van Biezen P, Kwekkeboom DJ, Kuijpers RW, Hooijkaas H, van Laar JA, Bastiaans J, Baarsma GS, van Hagen PM. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Am J Respir Crit Care Med 2011; 184: 1214-1216.
40. RP B. Tumor necrosis factor inhibition in treating sarcoidosis: the American experience. Revista Portuguesa de Pneumonologia 2007; 13: S47-S50.
41. Marcella S, Welsh B, Foley P. Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis. Australas J Dermatol 2011; 52: e8-11.
42. Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, Samimi M, Pavy S, Pertuiset E, Toussirot E, Combe B, Morel J. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009; 48: 883-886.
43. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011; 183: 573-581.
44. Grunewald J. Genetics of sarcoidosis. Curr Opin Pulm Med 2008; 14: 434-439.
45. Sweiss NJ, Zhang W, Franek BS, Kariuki SN, Moller DR, Patterson KC, Bennett P, Girijala LR, Nair V, Baughman RP, Garcia JG, Niewold TB. Linkage of type I interferon activity and TNF-alpha levels in serum with sarcoidosis manifestations and ancestry. PLoS One 2011; 6: e29126.